News

Early findings from a national study are shedding light on differences in the type and prevalence of mental disorders in US-born and immigrant Latinos, as well as differences among Latinos from various countries of origin.

Psychiatry is the go-to specialty for determining whether a patient in need of inpatient hospitalization or has an alternative motivation?

Studies have shown that many pharmacologic agents are effective in the treatment of acute mania and bipolar relapse education.

NEW YORK -- Low birth weight and child abuse combine synergistically to increase the later risks of depression by 10-fold and social dysfunction by nearly ninefold, researchers here said.

Pharmacotherapy of Acute Schizophrenia

Risk Factors for Suicide in Patients With Schizophrenia

Reading the Ability of a Patient to Change His or Her Life

From Our Readers

Poetry of the Times

DVD Aims to Educate Clinicians, Patients on Borderline Personality Disorder

Despite significant advances in our understanding of the nature of the disease and development of more effective treatments, schizophrenia remains one of the most challenging medical conditions of our time.

On Taking the Helm

Persons with childhood-onset schizophrenia appear to have the poorest outcome among those in whom schizophrenia is diagnosed.

The Metabolic Syndrome and Schizophrenia: Clinical Research Update

Depression and Diet in Elderly Community-Dwelling Mexican and European Americans

Adult Growth, Internalizations, and Synaptogenesis

Nonconventional and Integrative Treatments of Alcohol and Substance Abuse (Part 1)

Psychological Therapies for Schizophrenia: Family and Cognitive Interventions

Treatment of Low Back Pain

New Act by Congress Gives Boost to Autism Research

Biological Markers and the Future of Early Diagnosis and Treatment in Schizophrenia

Organized and early acute stroke treatment has been shown to improve functional deficits, reduce the need for institutionalization after stroke, and reduce patient mortality. Today, stroke research has evolved to incorporate an integrated, multidisciplinary treatment approach. Data from a study done in 2005 in Ontario, Canada, demonstrate the utility of providing rapid and integrated acute stroke treatment in a real-world setting. The study evaluated functional outcomes associated with rehabilitation services that are part of a flagship stroke treatment program initiated by the Ontario government. The hope for the future is that this approach to patient management will reduce associated health care costs, which are anticipated to increase dramatically in the coming decades.

Sudden infant death syndrome (SIDS) is the leading cause of postneonatal death in the United States.1 This unfortunate disorder is characterized by the sudden, unexpected death of an of infant between ages 1 and 12 months whose cause of death remains a mystery in the aftermath of a thorough postmortem examination that includes an autopsy, an investigation of the death scene, and a careful review of the infant's medical history. New research, published in the November 2006 issue of The Journal of the American Medical Association,2 that made recent headlines confirmed earlier research by the same investigative team3,4 showing that serotonergic brain stem abnormalities may be the at the root of SIDS.

In recent months, it's been the rare week that doesn't come with a report about the dangers of antidepressants. These drugs do have their drawbacks, but the dangers they pose are not their main problem. Their biggest shortcoming is that they don't work very well; fewer than half of the patients treated with them get complete relief, and that relief takes an unacceptably long time 2 o 3 weeks t kick in.

Letters to the Editor

PD is a common and challenging neurodegenerativemotor disorder, affecting at least a half millionpersons in the United States, according to the NationalInstitute of Neurological Disorders and Stroke. Withthe aging of the population, incidence is expected toincrease.

A panel of Proteonomic Biomarkers found withinCerebrospinal fluid (csf) may be the key to early differentiationOf alzheimer disease (AD) from other dementias.

The connection between Parkinson disease (PD) and melanoma is becoming increasingly apparent, leading some researchers to call for increased melanoma screening in the PD population. In addition, researchers are disproving previous theories that levodopa may be implicated in the link between melanoma and PD.

Patients with PD may be at more than twice the risk for the development of malignant melanoma than the general population, according to research by John M. Bertoni, MD, PhD, professor and chair of the Department of Neurology at Creighton University, Omaha, and colleagues.1 He presented the results of this research at the American Neurological Association's 131st Annual Meeting this past October in Chicago.

Theories about the causes of Parkinson disease (PD) are as tangled as the neurofilament proteins of Lewy bodies. However, investigators are teasing out threads of evidence that increasingly implicate environmental factors--perhaps aided and abetted by genetics--as contributors to this common neurodegenerative disorder.